Market Cap 9.65B
Revenue (ttm) 2.76B
Net Income (ttm) -1.03B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 1,167.56
Profit Margin -37.29%
Debt to Equity Ratio 0.00
Volume 2,839,800
Avg Vol 2,904,334
Day's Range N/A - N/A
Shares Out 188.64M
Stochastic %K 34%
Beta 0.98
Analysts Strong Sell
Price Target $68.74

Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic,...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 608 284 5700
Address:
5505 Endeavor Lane, Madison, United States
Woodman7
Woodman7 Jun. 26 at 4:19 PM
$EXAS - Tomorrow the US Supreme Court will make a ruling on the Braidwood case re:ACA required to cover preventative care eg cancer screening. Has been considered to be potentially impactful to $EXAS , but in reality I don’t really think it will affect whether or not people screen for colon cancer. Maybe I’m being naïve, but perhaps it would push people to the cheaper option versus a colonoscopy.
1 · Reply
bearcreekzeke
bearcreekzeke Jun. 26 at 2:19 PM
$EXAS https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=EXAS
1 · Reply
BullYa
BullYa Jun. 26 at 12:41 PM
1 · Reply
Woodman7
Woodman7 Jun. 26 at 1:23 AM
$EXAS - 3.4m Americans turned 45 (eligible for colon cancer screening) in 2024. That increases to 3.6m in 2025 - a 5.9% growth - just another tailwind for Cologuard.
0 · Reply
BullYa
BullYa Jun. 25 at 4:14 PM
$EXAS looks like it wants going down more 📉👀
0 · Reply
mrbud9
mrbud9 Jun. 25 at 3:35 PM
$EXAS tired of the seemingly endlessly kicking down the road to next quarter as others are moving and passing ( GH ) how long have they talked about their blood test ? Was a great company when had the field to themselves.
1 · Reply
BullYa
BullYa Jun. 25 at 1:31 PM
$EXAS 40 was it’s 1 yr low. 👀
0 · Reply
mrbud9
mrbud9 Jun. 24 at 10:12 PM
$EXAS kinda ridiculous, really wish would've sold years ago when was $150 for a minute. I've been in for probably 15yrs. and really for the first time thinking of moving on. Conway seems to not care anymore.
2 · Reply
bearcreekzeke
bearcreekzeke Jun. 24 at 7:15 PM
$EXAS WTF is going on here folks??? Super ugly day. Hopefully this isn't a reaction to some really bad news with us being the last ones to know. https://www.reddit.com/r/exactsciences/comments/1ljdnxu/exact_sciences_shares_catch_a_summer_cold/
0 · Reply
BullYa
BullYa Jun. 24 at 6:53 PM
$EXAS down vs the market is up huge.
0 · Reply
Latest News on EXAS
Exact Sciences to Participate in June Investor Conference

May 27, 2025, 4:05 PM EDT - 4 weeks ago

Exact Sciences to Participate in June Investor Conference


Exact Sciences Earns 2025 Great Place To Work® Certification™

May 12, 2025, 10:00 AM EDT - 6 weeks ago

Exact Sciences Earns 2025 Great Place To Work® Certification™


Exact Sciences to Participate in May Investor Conference

May 2, 2025, 6:00 AM EDT - 7 weeks ago

Exact Sciences to Participate in May Investor Conference


Exact Sciences Announces First-Quarter 2025 Results

May 1, 2025, 4:05 PM EDT - 2 months ago

Exact Sciences Announces First-Quarter 2025 Results


Exact Sciences Schedules First Quarter 2025 Earnings Call

Apr 1, 2025, 6:00 AM EDT - 3 months ago

Exact Sciences Schedules First Quarter 2025 Earnings Call


Exact Sciences to Participate in March Investor Conferences

Feb 24, 2025, 6:00 AM EST - 4 months ago

Exact Sciences to Participate in March Investor Conferences


Exact Sciences Announces Fourth Quarter 2024 Results

Feb 19, 2025, 4:05 PM EST - 4 months ago

Exact Sciences Announces Fourth Quarter 2024 Results


Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

Feb 3, 2025, 6:00 AM EST - 5 months ago

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call


Exact Sciences Announces Preliminary Fourth Quarter 2024 Results

Jan 12, 2025, 7:00 PM EST - 5 months ago

Exact Sciences Announces Preliminary Fourth Quarter 2024 Results


Why Is Exact Sciences Stock Trading Higher On Monday?

Nov 26, 2024, 12:21 PM EST - 7 months ago

Why Is Exact Sciences Stock Trading Higher On Monday?


Exact Sciences to Participate in December Investor Conferences

Nov 26, 2024, 6:00 AM EST - 7 months ago

Exact Sciences to Participate in December Investor Conferences


Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount

Nov 6, 2024, 12:36 PM EST - 8 months ago

Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount


Exact Sciences Announces Third-Quarter 2024 Results

Nov 5, 2024, 4:05 PM EST - 8 months ago

Exact Sciences Announces Third-Quarter 2024 Results


Exact Sciences to Participate in November Investor Conference

Nov 1, 2024, 6:00 AM EDT - 8 months ago

Exact Sciences to Participate in November Investor Conference


Exact Sciences Schedules Third Quarter 2024 Earnings Call

Oct 8, 2024, 6:00 AM EDT - 9 months ago

Exact Sciences Schedules Third Quarter 2024 Earnings Call


FMR LLC Bolsters Stake in Exact Sciences Corp

Oct 7, 2024, 2:05 PM EDT - 9 months ago

FMR LLC Bolsters Stake in Exact Sciences Corp


Woodman7
Woodman7 Jun. 26 at 4:19 PM
$EXAS - Tomorrow the US Supreme Court will make a ruling on the Braidwood case re:ACA required to cover preventative care eg cancer screening. Has been considered to be potentially impactful to $EXAS , but in reality I don’t really think it will affect whether or not people screen for colon cancer. Maybe I’m being naïve, but perhaps it would push people to the cheaper option versus a colonoscopy.
1 · Reply
bearcreekzeke
bearcreekzeke Jun. 26 at 2:19 PM
$EXAS https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=EXAS
1 · Reply
BullYa
BullYa Jun. 26 at 12:41 PM
1 · Reply
Woodman7
Woodman7 Jun. 26 at 1:23 AM
$EXAS - 3.4m Americans turned 45 (eligible for colon cancer screening) in 2024. That increases to 3.6m in 2025 - a 5.9% growth - just another tailwind for Cologuard.
0 · Reply
BullYa
BullYa Jun. 25 at 4:14 PM
$EXAS looks like it wants going down more 📉👀
0 · Reply
mrbud9
mrbud9 Jun. 25 at 3:35 PM
$EXAS tired of the seemingly endlessly kicking down the road to next quarter as others are moving and passing ( GH ) how long have they talked about their blood test ? Was a great company when had the field to themselves.
1 · Reply
BullYa
BullYa Jun. 25 at 1:31 PM
$EXAS 40 was it’s 1 yr low. 👀
0 · Reply
mrbud9
mrbud9 Jun. 24 at 10:12 PM
$EXAS kinda ridiculous, really wish would've sold years ago when was $150 for a minute. I've been in for probably 15yrs. and really for the first time thinking of moving on. Conway seems to not care anymore.
2 · Reply
bearcreekzeke
bearcreekzeke Jun. 24 at 7:15 PM
$EXAS WTF is going on here folks??? Super ugly day. Hopefully this isn't a reaction to some really bad news with us being the last ones to know. https://www.reddit.com/r/exactsciences/comments/1ljdnxu/exact_sciences_shares_catch_a_summer_cold/
0 · Reply
BullYa
BullYa Jun. 24 at 6:53 PM
$EXAS down vs the market is up huge.
0 · Reply
thingkfast
thingkfast Jun. 24 at 6:52 PM
$EXAS crc blood results and cancerguard launch soon, yet no momentum??
1 · Reply
BullYa
BullYa Jun. 24 at 6:17 PM
$EXAS looks like it wants back to 45 soon
0 · Reply
Mustardill
Mustardill Jun. 24 at 4:29 PM
$EXAS 5 straight years going down…. 9/10 straight red days…. this stock is going bankrupt… sell!
1 · Reply
anachartanalyst
anachartanalyst Jun. 24 at 4:02 PM
$EXAS https://anachart.com/wp-content/uploads/ana_temp/1750780910_soc-img.jpg
0 · Reply
investorjustin
investorjustin Jun. 24 at 3:46 PM
$EXAS what’s going on here?
1 · Reply
JarvisFlow
JarvisFlow Jun. 24 at 3:20 PM
Barclays updates rating for Exact Sciences ( $EXAS ) to Overweight, target set at 75 → 65.
1 · Reply
Mustardill
Mustardill Jun. 23 at 4:36 PM
$EXAS does this ever go up??? Not even a bounce off the 200 day
1 · Reply
Jasooon
Jasooon Jun. 22 at 11:51 AM
0 · Reply
GoldenTradesCapital
GoldenTradesCapital Jun. 21 at 1:07 PM
Top 5 Biotech Stocks to Keep on Watch 🔬 • $EXAS – Early cancer detection • $CRSP – Gene editing pioneer • $VRTX – Dominates cystic fibrosis • $MRNA – Expanding into RSV and flu • $TMDX – Organ transport tech Follow us for more daily alerts like this one 🔱
0 · Reply
GoldenTradesCapital
GoldenTradesCapital Jun. 19 at 5:56 PM
$EXAS – Leading the Future of Cancer Detection 🧬 A leader in early cancer detection, $EXAS is gaining traction with its Cologuard test and a growing pipeline of liquid biopsy products. Strong partnerships with health providers position it for durable growth. For more smart picks like this, follow us 🔱
0 · Reply
Mustardill
Mustardill Jun. 18 at 3:59 PM
$EXAS starting to feel bad for how much this stock lags compared to $GH and $NTRA. Can’t say I didn’t tell you.
2 · Reply
bearcreekzeke
bearcreekzeke Jun. 18 at 3:37 PM
$EXAS May 27, 2025 CFRA Adds Exact Sciences Corporation to the Small/Mid-Cap Growth Portfolio (EXAS 56.95): We are adding EXAS, a leading global cancer screening and diagnostics company, to the portfolio as we think current valuations offer an attractive entry point given EXAS’s superior growth outlook versus peers. We are encouraged by the company’s product portfolio, specifically its flagship colorectal cancer screening test (Cologuard) as well as Oncotype IQ cancer diagnostic tests and services. We forecast EXAS to become profitable starting in 2025, reversing net losses recorded in previous years, with the new version of the company’s Cologuard Plus positively impacting both revenue and margin expansion over time, which comes with a higher selling price and a lower cost per unit. Our 12-month target price of $65 is based on our DCF model, which assumes a beta of 1.25, a terminal growth rate of 2.5%, and a WACC of 11%. EXAS replaces Tandem Diabetes Care.
0 · Reply